uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
Show others and affiliations
2006 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 91, no 5, 667-670 p.Article in journal (Refereed) Published
Abstract [en]

The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.

Place, publisher, year, edition, pages
2006. Vol. 91, no 5, 667-670 p.
Keyword [en]
MDS, ATG, cyclosporine A, treatment
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-124615PubMedID: 16670072OAI: oai:DiVA.org:uu-124615DiVA: diva2:317775
Available from: 2010-05-05 Created: 2010-05-05 Last updated: 2010-05-06Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Sciences
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 133 hits
ReferencesLink to record
Permanent link

Direct link